More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Butyrolactone 3 [778649-18-6]
Chemical Structure
Chemical Structure
Chemical Structure

Butyrolactone 3 [778649-18-6]

Research Use Only
AG-CR1-3522
AdipoGen Life Sciences
CAS Number778649-18-6
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>95% (NMR)
Molecular Weight184.2
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Butyrolactone 3 [778649-18-6]
  • Delivery Days Customer
    10
  • CAS Number
    778649-18-6
  • Certification
    Research Use Only
  • Estimated Purity
    >95% (NMR)
  • Hazard Information
    Non-hazardous,Warning
  • Molecular Formula
    C9H12O4
  • Molecular Weight
    184.2
  • Scientific Description
    Chemical. CAS: 778649-18-6. Formula: C9H12O4. MW: 184.2. Synthetic Specific histone acetyltransferase Gcn5 inhibitor. Anticancer compound. Pre-mRNA splicing inhibitor. Blocks splicing before the first catalytic steps. Potential anti-inflammatory compound. - Specific histone acetyltransferase Gcn5 inhibitor [1, 2]. Anticancer compound [2, 4]. Pre-mRNA splicing inhibitor. Blocks splicing before the first catalytic steps [3]. Potential anti-inflammatory compound.
  • SMILES
    CCC[C@@H]1OC(=O)C(=C)[C@H]1C(O)=O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5: M. Biel, et al.; Angew. Chem. Int. Ed. Engl. 43, 3974 (2004)
  • Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties: A. Mai, et al.; J. Med. Chem. 49, 6897 (2006)
  • Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation: A.N. Kuhn, et al.; RNA 15, 153 (2009)
  • GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia: T. Holmlund, et al.; Leukemia 27, 578 (2013)